List of Excipients in Branded Drug DOXERCALCIFEROL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Hospira Inc	DOXERCALCIFEROL	doxercalciferol	0409-1331	ALCOHOL
Hospira Inc	DOXERCALCIFEROL	doxercalciferol	0409-1331	BUTYLATED HYDROXYTOLUENE
Hospira Inc	DOXERCALCIFEROL	doxercalciferol	0409-1331	EDETATE DISODIUM
Hospira Inc	DOXERCALCIFEROL	doxercalciferol	0409-1331	POLYSORBATE 20
Hospira Inc	DOXERCALCIFEROL	doxercalciferol	0409-1331	SODIUM CHLORIDE
Hospira Inc	DOXERCALCIFEROL	doxercalciferol	0409-1331	SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
Hospira Inc	DOXERCALCIFEROL	doxercalciferol	0409-1331	SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

Generic Drugs Containing DOXERCALCIFEROL

Company	Ingredient	NDC	Excipient
West-Ward Pharmaceuticals Corp	doxercalciferol	0054-0338	ALCOHOL
West-Ward Pharmaceuticals Corp	doxercalciferol	0054-0338	AMMONIA
West-Ward Pharmaceuticals Corp	doxercalciferol	0054-0338	BUTYL ALCOHOL
West-Ward Pharmaceuticals Corp	doxercalciferol	0054-0338	BUTYLATED HYDROXYANISOLE
West-Ward Pharmaceuticals Corp	doxercalciferol	0054-0338	D&C YELLOW NO. 10
West-Ward Pharmaceuticals Corp	doxercalciferol	0054-0338	FD&C RED NO. 40
West-Ward Pharmaceuticals Corp	doxercalciferol	0054-0338	FERROSOFERRIC OXIDE

What are the Most Frequently-Used Excipients in DOXERCALCIFEROL?

# Of NDCs	Excipient
13	ALCOHOL
2	AMMONIA
1	BUTYL ALCOHOL
4	BUTYLATED HYDROXYANISOLE
9	BUTYLATED HYDROXYTOLUENE
2	D&C YELLOW NO. 10
10	EDETATE DISODIUM

Excipient Strategy and Commercial Opportunities for Doxercalciferol

Last updated: February 26, 2026

What are the key excipient considerations for Doxercalciferol formulations?

Doxercalciferol is a vitamin D analog used primarily for secondary hyperparathyroidism in chronic kidney disease. Its formulation challenges include solubility issues, stability concerns, and bioavailability optimization.

Key excipient considerations:

• Solubilizers: Doxercalciferol exhibits low aqueous solubility. Solubilizers like polysorbates (e.g., Tween 80), cyclodextrins, or lipid-based excipients can enhance dissolution.
• Stabilizers: Protects against photodegradation and oxidation. Antioxidants such as ascorbyl palmitate or tocopherols are common.
• Carriers: For oral delivery, oils or softgel capsules are typical to ensure bioavailability.
• pH modifiers: To maintain stability, buffers like citrate or phosphate buffers are used.
• Excipients for controlled release: Matrix systems or coated particles can facilitate extended-release formulations, increasing patient adherence.

What formulation strategies are currently employed to optimize Doxercalciferol delivery?

The following strategies are prominent:

Strategy	Description	Benefits	Examples
Lipid-based formulations	Use of oils or lipid nanoparticles	Enhance solubility and bioavailability	Softgel capsules, nanoemulsions
Cyclodextrin complexes	Inclusion complexes with cyclodextrins	Improve dissolution	Hydroxypropyl-β-cyclodextrin-based systems
Microencapsulation	Encapsulation within polymer matrices	Control release	PLGA-based microcapsules
Solid dispersions	Dispersing drug in inert carriers	Increase dissolution rate	PVP or HPMC-based systems

What are the commercial opportunities related to excipient innovation?

The market for vitamin D analogs, including doxercalciferol, is growing driven by chronic kidney disease prevalence. Opportunities include:

• Formulation differentiation: Developing extended-release or targeted delivery systems can command premium pricing. For example, controlled-release formulations reduce dosing frequency, improving adherence.
• Patent protection: Innovating excipient combinations or delivery methods may provide patent barriers, extending product lifecycle.
• Market expansion: Combining doxercalciferol with novel excipients can enable formulations suitable for diverse routes, including injectable or transdermal, opening new markets.

Reported global vitamin D analogs market size was valued at USD 1.2 billion in 2021, with growth driven by aging populations and chronic conditions [1].

What regulatory considerations influence excipient selection?

Regulatory agencies, like the FDA and EMA, emphasize excipient safety, stability, and consistency. Approval pathways for excipient modifications are rigorous, requiring:

• Comprehensive qualification processes.
• Demonstration of excipient impact on drug stability and bioavailability.
• Use of excipients with recognized safety profiles or those already approved for similar uses.

What commercial strategies can optimize manufacturing and supply?

• Sourcing: Secure supply of high-grade, highly stable excipients with consistent quality.
• Formulation flexibility: Develop formulations adaptable to regional regulatory requirements regarding excipients.
• Cost management: Optimize excipient choice to balance performance and production cost.

Conclusion

Targeted excipient selection enhances Doxercalciferol bioavailability and stability. Formulation innovation, patent protection, and regulatory compliance are key to capturing market opportunities. Developing different delivery systems and leveraging excipient patents can transition into differentiated products with potential for premium pricing and broader market penetration.

---

Key Takeaways

• Solubilizers and stabilizers are critical in Doxercalciferol formulation to address solubility and stability.
• Lipid-based systems, cyclodextrin complexes, and controlled-release technologies are main strategies.
• Market growth stems from aging populations and chronic kidney disease prevalence.
• Innovation in excipient combinations can extend patent protection and product differentiation.
• Regulatory constraints demand rigorous safety and quality standards for excipient use.

---

Frequently Asked Questions

1. How do cyclodextrins improve Doxercalciferol bioavailability?
Cyclodextrins form inclusion complexes with Doxercalciferol, increasing its aqueous solubility and dissolution rate, which enhances absorption.

2. What excipients are typically used in softgel formulations of Doxercalciferol?
Oils (e.g., soybean, MCT), gelatin, glycerin, and stabilizers such as antioxidants.

3. Can controlled-release formulations be developed for Doxercalciferol?
Yes. Polymer matrices like HPMC or PLGA can control drug release, reducing dosing frequency.

4. Are there any excipients with known regulatory issues for vitamin D analog formulations?
Excipients with limited safety data or restricted usage, such as certain novel polymers or preservatives, may delay approval. Choosing excipients with established safety profiles mitigates risks.

5. What are the main drivers for innovation in Doxercalciferol excipient strategies?
Market growth, patent lifecycle extension, patient compliance, and formulation stability under varying storage conditions.

---

References

[1] Market Research Future. (2022). Vitamin D Analog Market Size, Share & Trends Analysis Report.